Capstone Therapeutics Corp. (CAPS)

5.0000 0.0000 (0.00%) As of 10:46AM EDT. Market open.

Capstone Therapeutics Corp.

1275 West Washington Street
Suite 104
Tempe, AZ 85281
United States
602-286-5520
https://www.capstonethx.com

Sector(s): Basic Materials
Industry: Building Materials
Full-time employees: 46

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Michael M. Toporek III	CEO, President & Chairman	48k	N/A	1966
Mr. Edward C. Schultz	VP, CFO & Treasurer	200k	N/A	1985
Mr. Matthew E. Lipman	VP, Secretary & Director	48k	N/A	1979

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Capstone Holding Corp., through its subsidiaries, engages in the distribution of masonry stone products in the United States. Its masonry stone products include manufactured and natural stone cladding products, natural stone landscape products and related goods for residential and commercial construction. The company was formerly known as Capstone Therapeutics Corp. and changed its name to Capstone Holding Corp. in February 2022. Capstone Holding Corp. was incorporated in 1987 and is headquartered in Tempe, Arizona. Capstone Holding Corp. operates as a subsidiary of BP Peptides, LLC.

Corporate governance

Capstone Therapeutics Corp.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.